Position in MDGL
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$387,140
+$16,000 QoQ
Shares Held
721
+1.7% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#270
of 414 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in MDGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CENTAURUS FINANCIAL, INC. holds $5,779,268 across 11 Biotechnology names. MDGL ranks #4 (6.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
23,928 | $1,872,844 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,749 | $1,365,510 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
65,576 | $1,112,824 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
This page
|
721 | $387,140 | |
| 5 | MRNA |
Moderna, Inc.
|
4,477 | $313,524 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
2,454 | $272,467 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
1,774 | $144,598 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
3,554 | $125,776 |
All Filings in MDGL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $387,140 | 721 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $371,140 | 709 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $412,879 | 709 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $325,189 | 709 | Shares | Sole | 2025-11-20 | |
| 2025-06-30 | $204,282 | 675 | Shares | Sole | 2025-08-29 | |
| 2025-03-31 | $228,548 | 690 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $212,913 | 690 | Shares | Sole | 2025-03-12 | |
| 2024-09-30 | $129,666 | 611 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $163,333 | 583 | Shares | Sole | 2024-09-23 | |
| No filing history on record for this holder in this stock. | ||||||